Shahidi M - Search Results

1

Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.

Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA. Shahidi M, et al. Cancer. 2002 Aug 1;95(3):520-30. doi: 10.1002/cncr.10691. Cancer. 2002. PMID: 12209744 Free article.

2

Cardiovascular disease as a long-term complication of treatment for testicular cancer.

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Huddart RA, et al. Among authors: shahidi m. J Clin Oncol. 2003 Apr 15;21(8):1513-23. doi: 10.1200/JCO.2003.04.173. J Clin Oncol. 2003. PMID: 12697875

3

Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.

Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A. Shahidi M, et al. Radiother Oncol. 2006 Jan;78(1):1-5. doi: 10.1016/j.radonc.2005.10.018. Epub 2005 Nov 22. Radiother Oncol. 2006. PMID: 16309770

4

Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer.

Murthy V, Norman AR, Shahidi M, Parker CC, Horwich A, Huddart RA, Bange A, Dearnaley DP. Murthy V, et al. Among authors: shahidi m. BJU Int. 2006 Mar;97(3):476-9. doi: 10.1111/j.1464-410X.2006.06013.x. BJU Int. 2006. PMID: 16469011

5

Diethylstilbestrol in castration-resistant prostate cancer.

Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, Horwich A, Dearnaley D. Wilkins A, et al. Among authors: shahidi m. BJU Int. 2012 Dec;110(11 Pt B):E727-35. doi: 10.1111/j.1464-410X.2012.11546.x. Epub 2012 Oct 30. BJU Int. 2012. PMID: 23110500 Clinical Trial.

6

Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.

Shahidi M, Norman AR, Gadd J, Huddart RA, Horwich A, Dearnaley DP. Shahidi M, et al. Clin Oncol (R Coll Radiol). 2001;13(4):291-5. doi: 10.1053/clon.2001.9272. Clin Oncol (R Coll Radiol). 2001. PMID: 11554629

7

Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer.

Mangar SA, Foo K, Norman A, Khoo V, Shahidi M, Dearnaley DP, Horwich A, Huddart RA. Mangar SA, et al. Among authors: shahidi m. Clin Oncol (R Coll Radiol). 2006 Aug;18(6):466-73. doi: 10.1016/j.clon.2006.04.008. Clin Oncol (R Coll Radiol). 2006. PMID: 16909970

8

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.

Dearnaley DP, Norman AR, Shahidi M. Dearnaley DP, et al. Among authors: shahidi m. J Urol. 1999 Jul;162(1):170. doi: 10.1097/00005392-199907000-00057. J Urol. 1999. PMID: 10379777 No abstract available.

9

In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.

Dearnaley DP, Norman AR, Shahidi M. Dearnaley DP, et al. Among authors: shahidi m. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):981; author reply 981. doi: 10.1016/s0360-3016(02)03001-8. Int J Radiat Oncol Biol Phys. 2002. PMID: 12377353 No abstract available.

10

Heterotopic bone formation: irradiation of high risk patients.

Cornes PG, Shahidi M, Glees JP. Cornes PG, et al. Among authors: shahidi m. Br J Radiol. 2002 May;75(893):448-52. doi: 10.1259/bjr.75.893.750448. Br J Radiol. 2002. PMID: 12036839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters